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Introduction
CRAC channel opening and SOCE are triggered by the engage-
ment of a variety of cell surface receptors including immunorecep-
tor tyrosine-based activation motif (ITAM)-containing receptors 
on T cells (TCR), B cells (BCR) and platelets (GPVI, CLEC2) as 
well as G protein coupled receptors (GPCR) such as chemokine 
receptors on immune cells and the receptors for thrombin and 
ADP on platelets (Fig. 1). Cellular stimulation via immunorecep-
tors and GPCRs leads to the activation of phospholipase Cγ and 
Cβ, respectively, both of which result in the production of the 





to and opens InsP3 receptor channels in the membrane of the 
ER causing the efflux of Ca2+ from the ER and a reduction of the 
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Store-operated Ca2+ entry (SOCE) is an important Ca2+ influx 
pathway, which is defined by the fact that depletion of 
intracellular Ca2+ stores, mainly the endoplasmic reticulum (ER), 
triggers the opening of Ca2+ channels in the plasma membrane. 
The best characterized SOC channel is the Ca2+ release-
activated Ca2+ (CRAC) channel, which was first described in 
cells of the immune system but has since been reported in 
many different cell types. CRAC channels are multimers of 
ORAI family proteins, of which ORAI1 is the best characterized. 
They are activated by stromal interaction molecules (STIM) 
1 and 2, which respond to the depletion of intracellular Ca2+ 
stores with oligomerization and binding to ORAI proteins. The 
resulting SOCE is critical for the physiological function of many 
cell types including immune cells and platelets. Recent studies 
using cell lines, animal models and primary cells from human 
patients with defects in SOCE have highlighted the importance 
of this Ca2+ entry mechanism in a variety of pathophysiological 
processes. This review focuses on the role of SOCE in immunity 
to infection, allergy, hemostasis, and cancer.
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Ca2+ concentration in the ER, or [Ca2+]
ER
. This triggers the open-
ing of CRAC channels in the plasma membrane and SOCE. The 
pore forming subunit of the CRAC channel is ORAI1,1-3 which 
is a tetraspanning plasma membrane (PM) protein. It is unrelated 
to other ion channels and was discovered by RNAi screens and 
positional cloning in patients with inherited CRAC channel dys-
function.4-6 Two homologs, ORAI2 and ORAI3, conduct Ca2+ 
currents when ectopically expressed in cells and may contribute 
to CRAC channel function and SOCE. Loss-of-function muta-
tions in the human ORAI1 gene and genetically engineered mice 
lacking functional ORAI1 channels have established its essential 
role in SOCE in many cell types.
ORAI1/CRAC channels are gated by stromal interaction mol-
ecule 1 (STIM1), a single-pass transmembrane protein located in 
the membrane of the ER that is activated in response to depletion 
of ER Ca2+ stores.7,8 STIM1 senses the depletion of ER Ca2+ stores 
via paired EF-hand Ca2+ binding domains in its ER lumenal 
N-terminus. Dissociation of Ca2+ from the EF-hands of STIM1 
results in its oligomerization and translocation to ER-plasma 
membrane (PM) junctions, where it forms large protein clus-
ters referred to as STIM1 puncta.9 STIM1 recruits ORAI1 to 
these puncta by binding to its intracellular N and C termini,10-12 
thereby opening CRAC channels and promoting Ca2+ influx. 
STIM2, like its homolog STIM1, also mediates SOCE but has 
slower kinetics of activation and is activated by weaker depletion 
of ER Ca2+ stores.13,14 While ORAI1 and STIM1 are necessary 
and sufficient to mediate SOCE,15,16 several proteins have been 
identified that modulate CRAC channel function and SOCE 
both positively and negatively.17 The molecular mechanisms 
underlying CRAC channel function have been reviewed in detail 
elsewhere.17-21
SOCE is critical for the activation and function of many non-
excitable cells, and emerging more recently, excitable cells such 
as neurons and muscle cells as well. Cell-based experiments in 
vitro, animal models and studies in human patients with defects 
in SOCE have revealed important roles of ORAI and STIM pro-
teins in a variety of physiological and pathophysiological processes 
including hypoxic neuronal cell death,22 cardiac hypertrophy23 
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in these patients, and defective immune responses 
by both systems are likely to contribute to their 
immunodeficiency.
Several loss-of-function or null mutations that 
abolish ORAI1 protein expression or function in T 
cells, B cells and neutrophils have been described.47-49 
The first mutation identified was a missense muta-
tion in ORAI1 that results in the substitution of a 
highly conserved arginine residue in the first TM 
domain of ORAI1 (ORAI1-R91W). It abolishes 
CRAC channel function despite normal ORAI1 
expression.4,50,51 R91 is located at the cytoplasmic 
face of the CRAC channel pore and its substitution 
with tryptophan is likely to establish a hydrophobic 
seal that occludes the channel pore.52 Other immu-
nodeficient patients lacking SOCE were found to 
be homozygous for nonsense (A88SfsX25) or mis-
sense (A103E, L194P) mutations in the ORAI1 
gene that abolish protein expression.47-49 In addi-
tion to ORAI1 mutations, patients with loss-of-
function and null mutations in the STIM1 gene 
lacked SOCE in immune cells. STIM1 protein 
expression was absent in patients with frameshift 
(E128RfsX9) or splice site (1,538–1 G > A) muta-
tions in STIM1.44,53 In addition, patients homozy-
gous for a missense mutation in STIM1 (R429C) 
express a nonfunctional form of STIM1 protein 
that abolishes Ca2+ influx in T cells and fibroblasts 
and results in severely impaired T cell function.46 
ORAI1 and STIM1 deficient patients suffer from 
an almost identical form of immunodeficiency, 
which we named CRAC channelopathy to empha-
size the causative role of impaired CRAC channel 
function in its pathogenesis. Besides immuno-
deficiency, disease in these patients is charac-
terized by autoimmunity, ectodermal dysplasia 
(impaired dental enamel calcification and eccrine 
sweat gland function) and muscular hypotonia 
(reviewed in refs. 42 and 43).
SOCE Regulates Adaptive Immune Function
Infections in CRAC channel deficient patients are caused by 
impaired T cell and NK cell activation as a consequence of abol-
ished SOCE.44,47-49,53-55 In T cells, SOCE is induced after antigen 
recognition by the T cell receptor and regulates many processes 
including T cell proliferation, apoptosis, cytokine gene expression 
and T cell differentiation. TCR mediated activation of T cells 
is severely impaired in the absence of SOCE as apparent from 
impaired proliferation and expression of cytokines such as IL-2, 
IL-4, TNFα and IFNγ in T cells from ORAI1 or STIM1 defi-
cient patients.47,53-55 Recently, SOCE was shown to be important 
for the regulation of T cell survival and activation-induced cell 
death. T cells from Orai1-/- mice were more resistant to apoptosis 
in vitro and in vivo due to reduced mitochondrial Ca2+ uptake 
and altered expression of proapoptotic and antiapoptotic factors 
during vascular injury.24-26 In this review, we will discuss the phe-
notype of CRAC channel deficient patients, the role of SOCE in 
immune cell function and immunity to infection,4,27-34 in platelet 
function and hemostasis35-39 as well as carcinogenesis.40,41
CRAC Channels in Immune Function
SOCE is essential for immunity to infection 
The role of SOCE in immunity to infection is underlined 
by the severe, recurrent infections with viral, bacterial, and 
fungal pathogens affecting patients with mutations in ORAI1 
and STIM1 genes that abolish SOCE.42,43 Patients are suscep-
tible to chronic and recurrent viral infections, especially with 
herpes viruses such as cytomegalovirus (CMV), Epstein Barr 
virus (EBV) and human herpes virus (HHV) 8.44-46 SOCE is 
impaired in cells of both the innate and adaptive immune system 
Figure 1. STIM1 and ORAI1 in platelet function. Stimulation of platelets with agonists 
such as thrombin, thromboxane A2, ADP, or collagen results in Ca2+ release from ER stores 
and SOCE. Ca2+ released from the ER activates the guanine nucleotide exchange factor, 
CalDAG-GEFI, which controls the activity of the small GTPase Rap1, a critical regulator of 
platelet responses such as integrin activation, secretion and spreading. STIM1 and ORAI1 
are the major homologs mediating SOCE in platelets. Sustained elevated [Ca2+]i resulting 
from SOCE is essential for activation of the enzyme scramblase, which exposes phos-
phatidylserine (PS) on the outer surface of the cell membrane. PS exposure allows for 
the binding of coagulation factors on the platelet surface, thereby stimulating the gen-
eration of thrombin at sites of vascular injury. Both the adhesive and the pro-coagulant 
























almost completely impaired SOCE in Stim1,2 deficient mice,30 
it is surprising that lack of SOCE in these mice and human 
patients lacking ORAI1 or STIM1 does not have a greater 
impact on B cell development or function. It is conceivable that 
small increases in [Ca2+]
i
 suffice for signal propagation or that 
other Ca2+ channels besides STIM1,2-activated channels medi-
ate Ca2+ influx in B cells.
SOCE Regulates the Function  
of Innate Immune Cells
Besides lymphocytes, CRAC channel currents and SOCE 
have also been observed in a variety of cells of the innate immune 
system such as neutrophils, monocytes/macrophages and natu-
ral killer (NK) cells. Neutrophils and NK cells from ORAI1 
deficient patients lack SOCE in response to store depletion and 
antigen receptor stimulation.49,51 NK cells are cytotoxic lympho-
cytes that are essential for immune responses against many viral 
infections and antitumor immunity. Intriguingly, ORAI1- and 
STIM1-deficient NK cells from patients showed impaired cyto-
kine production, failed to exocytose cytotoxic granules and were 
unable to lyse tumor target cells when coincubated in vitro.46,51 
Consistent with these findings, NK cells from Orai1KI/KI mice 
also showed reduced degranulation and cytotoxic function in 
vitro (SF, unpublished data). In addition to functional defects 
in NK cells, a STIM1 deficient patient completely lacked CD3+ 
Va24+ Vb11+ NKT cells in their peripheral blood. Likewise, 
NKT cell development was impaired in STIM1,2-deficient 
mice.142 These findings suggest that SOCE is important for the 
development of this subset of cytotoxic lymphocytes.46 NKT 
cells express a TCR that recognizes lipid and glycolipid anti-
gens presented by CD1d molecules. They share properties with 
NK cells such as the ability to produce IFN-γ. Impaired NKT 
cell development in the absence of SOCE is consistent with ear-
lier findings that the transcription factor early growth response 
protein 2 (Egr2) regulates NKT cell development.60 Since Egr2 
expression is regulated by the Ca2+ dependent transcription fac-
tor NFAT,61 SOCE is likely to contribute to NKT cell devel-
opment through its regulation of NFAT activation. Impaired 
function and development of NK and NKT cells, respectively, 
may contribute to impaired antiviral immunity in CRAC chan-
nel deficient patients, although the precise role of SOCE in these 
cells remains to be investigated.
As cells of the innate immune system, neutrophils and mac-
rophages have important functions in the killing of bacteria and 
other pathogens through their ability to phagocytose patho-
gens, to produce reactive oxygen species (ROS) and other effec-
tor mechanisms. SOCE in these cells is triggered by binding of 
IgG antibodies to Fc receptors (FcγR) or chemokines such as 
fMLP to chemokine receptors. SOCE mediated by ORAI1 chan-
nels regulates integrin-mediated arrest of neutrophils and thus 
potentially the ability of neutrophils to migrate to sites of inflam-
mation. Inhibition of SOCE in human neutrophils with 2-APB 
or deletion of Orai1 in mouse neutrophils delayed and impaired 
the arrest of neutrophils under shear stress conditions.62 This 
effect of Ca2+ influx via ORAI1 was proposed to be mediated by 
such as Fas ligand (CD178), Noxa and Mcl-1.56 In vivo stud-
ies using mice with complete or conditional, T-cell-specific dele-
tion of Orai1 or Stim1 genes confirmed that immune responses 
by CD4+ and CD8+ T cells are dependent on functional CRAC 
channels.31,32,34,57 T cell-specific deletion of Stim2, Stim1 or both 
Stim1 and Stim2 (Stim1,2) genes resulted in progressively greater 
defects in SOCE and T cell function. Lack of STIM2 in CD4+ T 
cells did not impair the acute peak of Ca2+ influx in the first min-
utes after T cell stimulation, but abolished sustained Ca2+ influx 
and activation of the Ca2+ dependent transcription factor NFAT 
measured over several hours after stimulation.32 By contrast, T 
cells lacking STIM1 or both STIM1,2 had strongly reduced 
peak and sustained Ca2+ levels.32 Accordingly, their produc-
tion of IL-2, IFN-γ and other cytokines was abolished, whereas 
STIM2 deficient T cells had a partial defect in cytokine produc-
tion. Therefore, both STIM1 and STIM2 contribute to SOCE 
in T cells, albeit to a different extent and with different kinetics. 
ORAI1 is indispensable for CRAC channel function and SOCE 
in human T cells because T cells from patients with loss-of-func-
tion or null mutations in ORAI1 lacked I
CRAC
 and SOCE, failed 
to proliferate in vitro and to produce cytokines. In contrast to 
human T cells, ORAI1 appears to be more redundant in naive 
mouse T cells, suggesting potential contributions of ORAI2 and 
ORAI3 to CRAC channel function. Ca2+ influx was reduced but 
not absent in naïve CD4+ and CD8+ T cells from Orai1-/- mice 
and Orai1KI/KI knockin mice, which express the non-functional 
ORAI1-R93W mutant.31,36 In another study, SOCE was normal 
in T cells from Orai1-/- mice.34 When cultured in vitro, ORAI1-
deficient T cells proliferated normally despite almost completely 
impaired SOCE in differentiated CD4+ T helper cells and CD8+ 
cytotoxic T cells.31,58 These findings suggest that the composition 
of CRAC channels in murine T cells may change during T cell 
differentiation and that naïve T cells may utilize not only ORAI1 
but also other ORAI homologs to conduct Ca2+. Regardless, 
T-cell-mediated immune responses in vivo require ORAI1 func-
tion because Orai1KI/KI mice failed to mount a hypersensitivity 
response in response to contact allergen exposure of the skin and 
showed impaired rejection of HLA mismatched skin allografts.31 
In addition, naïve CD4+ CD45RB+ T cells from Orai1KI/KI mice 
failed to induce inflammatory bowel disease (IBD) when adop-
tively transferred to T cell deficient Rag2-/- mice, indicating that 
the differentiation and/or function of proinflammatory T cells 
depends on functional CRAC channels.31
Like in T cells, SOCE in B cells is induced by antigen bind-
ing to the B cell receptor (BCR) and subsequent activation of 
protein tyrosine kinases and PLCγ.59 While cytokine produc-
tion and proliferation of murine B cells in vitro depended on 
SOCE mediated by ORAI1,58 STIM1 and STIM2,30 respec-
tively, the production of immunoglobulins by B cells was inde-
pendent of CRAC channels. Mice lacking either Stim1 alone 
or both Stim1 and Stim2 showed normal or slightly increased 
levels of IgM and IgG following immunization in vivo.30,57 In 
humans, ORAI1 and STIM1 deficiency was associated with 
normal serum Ig levels, whereas antigen specific antibodies 
were absent in some patients.53,54 Given the many Ca2+ depen-
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important to define the role of SOCE in the differentiation and 
function of distinct immune cell populations through the use of 
gene-targeted mice, selective CRAC channel inhibitors and the 
analysis of SOCE-deficient patients.
SOCE in mast cell function and allergy 
Mast cells are cells of the innate immune cells that are located 
predominantly at mucosal surfaces where they mediate a first-line 
response to infections with bacteria and parasites.76 In addition, 
mast cells are central players in (type I) hypersensitivity responses 
and allergic diseases such as rhinoconjunctivitis, asthma and 
anaphylaxis. Recognition of pathogens and allergens by the high 
affinity IgE receptor (FcεRI) at the mast cell surface triggers an 
increase in [Ca2+]
i
 and the release of granules containing a wide 
variety of proinflammatory mediators. Early studies had sug-
gested that Ca2+ influx is required for or modulates the extent 
of release of histamine containing granules from mast cells.77-79 
More recently, it has been shown that the microtubule-dependent 
translocation of cytoplasmic granules to the plasma membrane 
is Ca2+ independent, whereas their release by exocytosis requires 
Ca2+ signals.80
In murine mast cells, FcεRI mediated Ca2+ influx is mediated 
by ORAI1 and STIM1. Mast cells from Stim1-/- and Orai1-/- mice 
showed impaired SOCE in response to thapsigargin stimulation 
or FcεRI crosslinking.27,34 Importantly, the degranulation of 
mast cells lacking ORAI1 or STIM1 following FcεRI crosslink-
ing was strongly reduced.27,34 In addition, they failed to secrete 
proinflammatory cytokines (IL-6, TNF-α) and lipid media-
tors such as leukotriene (LT) C
4
. As a consequence, the passive 
cutaneous anaphylaxis response in vivo, which depends on mast 
cell activation, was attenuated,27,34 suggesting that SOCE may 
be essential for mast cell activation in allergic diseases.81 Indeed, 
ORAI1 was upregulated in cells of the nasal mucosa of mice sub-
jected to ovalbumin (OVA)-induced allergic rhinitis.82 Inhibition 
of SOCE in mice with allergic rhinitis by injection of 2-APB or 
by inhalation of siRNA against ORAI1 reduced the levels of 
inflammatory mediators and clinical symptoms in mice.83 In 
humans, SOCE was shown to play a role in mast cell activation 
in nasal polyposis, a chronic inflammatory disease of the upper 
respiratory tract. Polyps are rich in mast cells and eosinophils, 
which produce high levels of proinflammatory mediators such 
as LTC
4
. Blocking CRAC channel function with La3+ showed a 
strong synergistic effect with low dose LT receptor antagonists 
on inhibiting mast cell function,28 further indicating that SOCE 
is essential for mediating mast cell mediated inflammation in 
allergy.
ORAI1 and STIM1 in Platelet Function
Calcium and platelet activation 
Hemostasis at sites of vascular injury depends on the coordi-
nated activation of platelets and the clotting system. In platelets, 
the second messenger Ca2+ controls a variety of cellular responses, 
including integrin activation, secretion, shape change and pro-
coagulant activity.84-87 Engagement of platelet surface receptors 
with agonists such as thrombin, thromboxane A2, ADP or col-
lagen triggers the activation of phospholipase C, followed by 
Kindlin-3 and ORAI1/Ca2+ dependent consolidation of the inte-
grin LFA-1 into macroclusters at focal sites of adhesion.63
After arriving at sites of infection, neutrophils and macro-
phages phagocytose bacteria, which is an important mechanism 
to remove and subsequently kill pathogens. In neutrophils, 
phagocytosis following binding of opsonized particles to FcγR 
appears to be dependent on Ca2+ as chelating intracellular Ca2+ 
with BAPTA reduced phagocytosis in human neutrophils and 
HL-60 cells.64,65 However, phagocytosis is independent of 
SOCE as inhibition of Ca2+ influx in HL-60 cells with La3+, 
Gd3+ or the CRAC channel inhibitor BTP-2 did not impair 
phagocytosis and bacterial killing.65,66 In macrophages, con-
flicting results had been obtained regarding the role of Ca2+ 
in phagocytosis.67-69 More recently, a severe defect in FcγR-
dependent phagocytosis was described in SOCE-deficient 
peritoneal macrophages isolated from Stim1-/- mice when these 
were incubated with opsonized red blood cells in vitro.70 When 
Stim1-/- mice were injected with antibody-opsonized red blood 
cells (RBC) or platelets—common animal models of autoim-
mune hemolytic anemia and thrombocytopenia, respectively—
they developed less severe disease, which was interpreted as a 
defect in phagocytosis of RBC and platelets by SOCE deficient 
macrophages.70 Intriguingly, CRAC channel-deficient patients 
with mutations in STIM1 and ORAI1 genes suffer from autoim-
mune hemolytic anemia and thrombocytopenia due to autoan-
tibodies directed against RBC and platelets,43,46,47,53 indicating 
that SOCE may not be required for phagocytosis by cells of the 
mononuclear phagocyte system in humans, which is responsible 
for the removal of cells and pathogens. SOCE in macrophages 
from human ORAI1/STIM1 deficient patients could not be 
evaluated and it is unclear how impaired SOCE affects human 
macrophage function.
Pathogens sequestered within phagosomes of macrophages 
and neutrophils are killed following fusion of phagosomes with 
lysosomes. The phagosomal production of reactive oxygen spe-
cies (ROS) by NADPH oxidase is dependent on SOCE.66 When 
neutrophil granulocytes derived from the promyelocytic leuke-
mia cell line HL-60 were stimulated with fMLF in the presence 
of the CRAC channel inhibitor BTP2, their ROS production 
was significantly decreased. Follow-up studies showed that ROS 
production is dependent on STIM1 and ORAI1.65,71 The pre-
cise mechanisms through which SOCE regulates NADPH oxi-
dase function and ROS production remain to be established. 
They have been suggested to involve several kinases including 
protein kinase C (PKC), phosphoinositide 3-kinase (PI3K) and 
sphingosine kinase71,72 as well as the translocation of the Ca2+ 
binding proteins S100A8-A9 to the phagosomal membrane.65 
Like in neutrophils, ROS production in macrophages is depen-
dent on elevated [Ca2+]
i
 as were the production of nitric oxide 
(NO), secretion of microbicidal proteins and proinflammatory 
mediators.73-75
Given the emerging role of ORAI1 and STIM1 in NK cells, 
neutrophils, macrophages and potentially other cells in the innate 
immune system, it is likely that the immunodeficiency observed 
in CRAC channel deficient patients is due to a combination of 
























further identified CRAC currents with characteristics similar to 
those shown for ORAI1 channels in immune cells.
Four different mouse models have been used to evaluate the 
role of STIM1 and ORAI1 in platelet activation: mice lack-
ing expression of Stim1 (Stim1-/-)39 or Orai1 (Orai1-/-)37 genes, 
knock-in mice expressing a loss-of-function mutant of Orai1 
(Orai1R93W),36 and conditional knockout mice lacking Stim1 
expression selectively in platelets/megakaryocytes (Stim1f/f PF4-
Cre).35 To circumvent the perinatal lethality associated with the 
systemic loss of Stim1 or Orai1 gene expression, bone marrow 
chimeras were generated to delete STIM1 or ORAI1 in blood 
cells only.37,39 A similar approach was taken to generate chime-
ric mice that express ORAI1R93W in blood cells.36 Common to 
platelets from all four strains was an almost complete defect in 
SOCE. Deficiency or loss-of-function of ORAI1 did not affect 
Ca2+ mobilization from intracellular stores. Interestingly, plate-
lets from Stim1-/- mice also showed a defect in Ca2+ release from 
intracellular stores, suggesting that STIM1 is important for 
proper store refilling as well as SOCE in these cells. Platelets with 
impaired SOCE showed only minor defects in their ability to 
activate integrin αIIbβ3 or to release their granules in response 
to cellular stimulation, in particular when the cells were stimu-
lated via GPCRs. A more pronounced dependence on SOCE was 
observed for ITAM-dependent platelet activation. This is likely 
the result of weak activation of PLCγ2 downstream of ITAM-
coupled receptors, i.e., the very limited mobilization of Ca2+ from 
intracellular stores induced by such agonists.
While studies on the platelet activation response under static 
conditions yielded consistent results between the four mouse 
models, marked differences were seen in the ability of platelets 
with impaired function of STIM1 or ORAI1 to form thrombi 
under flow conditions ex vivo. In these studies, anticoagulated 
whole blood is perfused over a collagen surface in a microfluid-
ics device to mimic pathophysiological shear stress. Thrombus 
formation was significantly impaired in blood from both Stim1-
/- or Orai1-/- mice.37,39 In contrast, thrombus formation in this ex 
vivo system was normal in blood isolated from Stim1f/f PF4-Cre 
or Orai1R93W mice.35,36 Possible explanations for the discrepancy 
between these studies include variations in the experimental set-
ups, different levels of residual SOCE in platelets from Stim1f/f 
PF4-Cre and Orai1R93W vs. Stim1-/- and Orai1-/- mice, or adverse 
effects of irradiation (during the generation of bone marrow chi-
meric mice) on circulating platelets.
In contrast to the relatively minor defects in integrin acti-
vation and granule release, platelets with impaired STIM1 or 
ORAI1 function showed a more profound defect in their ability 
to switch to a pro-coagulant state. Compared with WT controls, 
phosphatidylserine (PS) exposure on the surface of activated 
platelets from Stim1-/-, Orai1-/-, Stim1f/f PF4-Cre, or Orai1R93W 
mice was markedly reduced.35,36,98 This defect was particularly 
strong when anticoagulated blood was perfused over collagen ex 
vivo, where the number of PS-positive cells adherent to collagen 
was reduced by 50–95% in the absence of functional STIM1 
or ORAI1. Gilio and colleagues further demonstrated that this 
defect in PS exposure correlated with impaired collagen-induced 
pro-coagulant activity of platelets from Stim1-/- or Orai1-/- mice 
generation of InsP3 and release of Ca2+ from intracellular stores 
of the endoplasmic reticulum (ER) (Fig. 1). Like in immune cells 
this depletion of Ca2+ stores is linked to the opening of CRAC 
channels in the plasma membrane and SOCE.88-90 Elevated 
[Ca2+]
i
 leads to the activation of CalDAG-GEFI, a Ca2+-sensitive 
guanine nucleotide exchange factor for small GTPases of the Rap 
family.91,92 Rap GTPases in turn modulate the activity of other 
signaling cascades important for platelet activation, such as MAP 
kinases93 or Rac GTPases.94 While these signaling responses 
are efficiently triggered in the absence of extracellular Ca2+, the 
conversion of a pro-adhesive to a pro-coagulant platelet strongly 
depends on agonist-induced Ca2+ entry.95,96 To achieve this pro-
coagulant state, platelets have to loose their membrane asymme-
try and express phosphatidylserine (PS) on the outer leaflet of the 
lipid bilayer. This negatively charged surface provides docking 
sites critical for the assembly and activation of plasma clotting 
factors, thus promoting the propagation of coagulation and the 
generation of a fibrin plug at sites of vascular injury.
Although SOCE had been established as a main mechanism 
for Ca2+ entry in platelets, the molecular machinery regulating 
this process has only recently been identified. In this part of the 
review, we will summarize important studies that (a) identified 
STIM1 and ORAI1 as regulators of SOCE in platelets, and (b) 
investigated the role of STIM1 and ORAI1 in platelet function 
in vitro and in vivo.
STIM1 and ORAI1 regulate SOCE in platelets 
The first evidence supporting a role for STIM1 in platelet 
SOCE came from studies in mice expressing a gain-of-function 
mutant of STIM1 (named Saxcoburggotski, Stim1Sax).38 In these 
mice, an aspartate at position 84 in the Ca2+ binding EF hand 
domain of STIM1 is replaced by a glycine, leading to a reduced 
ability of STIM1 to bind Ca2+, thereby mimicking store deple-
tion and resulting in constitutively active STIM1. Homozygosity 
for the D84G mutation in miceis lethal in utero due to dissemi-
nated bleeding. Mice heterozygous for the mutation (Stim1Sax/+) 
are viable but are severely thrombocytopenic due to increased 
platelet turnover (platelet counts < 10% of that in wild-type con-
trols). Stim1Sax/+ platelets are characterized by increased baseline 
[Ca2+]
i
 and mild pre-activation of the major integrin, αIIbβ3. 
When stimulated with thapsigargin, Stim1Sax/+ platelets showed 
faster store release but markedly impaired calcium entry (~70% 
reduction). Interestingly, Stim1Sax/+ platelets responded normally 
to stimulation via G protein-coupled receptors (GPCRs), while 
they were unresponsive to agonists of immunoreceptor tyrosine-
activation motif (ITAM)-based receptors. Thus, enhanced SOCE 
pre-activates platelets, leading to increased platelet clearance, but 
it also desensitizes platelets toward stimulation via ITAM recep-
tors. The consequence of the low platelet count and the ITAM 
activation defect is a significant protection of Stim1Sax/+ mice from 
arterial thrombosis.
Studies by Tolhurst and colleagues supported a critical role of 
STIM1 and ORAI1 in platelet SOCE.97 They showed that RNA 
transcripts for STIM1 and ORAI1 are expressed at much higher 
levels in platelets and megakaryocytes when compared with non-
selective cation channels such as TRPC1, TRPC6, or TRPM2. 
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critical regulator of platelet pro-coagulant activity in humans108 
and mice.109 The studies by Yang and colleagues elegantly 
documented that TMEM16F is a SCAN channel with a large 
pore that is permeable for cations, in particular Ca2+ and Ba2+. 
Heterologously expressed TMEM16F showed a small single 
channel conductance for Ca2+, suggesting that this SCAN 
channel may contribute to Ca2+ entry in platelets. Deficiency 
in TMEM16F in mice led to reduced platelet PS exposure, pro-
longed tail bleeding times, and protection from experimental 
thrombosis.109 Consistently, TMEM16F was identified as the 
gene affected in patients with Scott Syndrome, a rare bleeding 
disorder caused by impaired platelet pro-coagulant activity.108 At 
this point it is unclear how TMEM16F affects Ca2+-dependent 
scramblase activity in platelets.
Blockers of SOCE as antithrombotic agents 
To date, only one study investigated the effects of inhibitors 
of SOCE on platelet activation and thrombosis in vivo.110 In their 
work, van Kruchten and colleagues demonstrate that various 
established and novel SOCE inhibitors significantly reduce plate-
let PS exposure ex vivo. Compared with vehicle-treated controls, 
thrombus formation on collagen was slightly but significantly 
reduced. Importantly, mice treated with the SOCE inhibitor 
2-aminoethyl diphenylborate (2-APB) were characterized by a 
reduced platelet activation response and partial protection from 
experimental stroke after transient cerebral arterial occlusion. It 
should be noted, however, that 2-APB is a non-selective blocker 
of ORAI1 and SOCE and that it also inhibits the function of a 
variety of ion channels including Ins(1,4,5)P
3
R and TRP chan-
nels. Although 2-APB itself is therefore not useful as an anti-
thrombotic drug, more specific SOCE inhibitors may be suitable 
for the treatment of thrombosis.
STIM1 and ORAI1 in Cancer
SOCE mediated by ORAI and STIM proteins has recently 
been implicated in various cellular processes associated with car-
cinogenesis. These include, for instance, increased proliferation, 
escape from apoptosis, evasion of growth restriction and metas-
tasis.111 Dysregulated expression of Ca2+ channels and other mol-
ecules involved in Ca2+ homeostasis has been observed in several 
forms of cancer.112 In the following section, we will discuss recent 
evidence indicating that SOCE mediated by ORAI1 and STIM1 
may control key processes in carcinogenesis.
STIM1 and ORAI1 regulate proliferation and apoptosis of 
cancer cells 
Initial studies linking STIM1 to cancer observed that the 
gene locus encoding STIM1 on chromosome 11p15 was deleted 
in human rhabdomyosarcoma and rhabdoid tumor cell lines. 
Ectopic overexpression of STIM1 in vitro in G401 rhabdomyo-
sarcoma cells resulted in morphologic changes and ultimately 
in cell death.113,114 These findings, made long before the essen-
tial function of STIM1 in SOCE had been discovered, led to 
the hypothesis that STIM1 might function as a tumor suppres-
sor. More recently, a tumor suppressive function of SOCE was 
described by Flourakis et al., who showed that SOCE mediated 
by ORAI1 induces apoptosis in human prostate cancer cells and 
in vitro. Under coagulant conditions, however, PS exposure and 
thrombin-dependent generation of fibrin-rich thrombi were nor-
malized, suggesting that in vivo this defect may be compensated 
for by additional agonists such as thrombin.
Stim1-/- and Orai1-/- mice have been subjected to various in 
vivo models of thrombosis, including arterial thrombosis in the 
microcirculation and the carotid artery. In all models, impaired 
SOCE led to a significant protection of mice from vessel occlu-
sion, presumably due to impaired platelet function. However, 
these studies were done with chimeric mice lacking Stim1 or 
Orai1 gene expression in all hematopoietic cells, including 
inflammatory cells known to play a role in arterial thrombo-
sis99 and ischemia reperfusion injury in stroke.100 To specifically 
address whether SOCE in platelets is critical for arterial throm-
bosis, we studied thrombus formation in Stim1f/f PF4-Cre mice 
by intravital microscopy.35 Similar to previous work with chime-
ric mice, we found thrombi in Stim1f/f PF4-Cre mice to be less 
stable. Thrombus instability in Stim1f/f PF4-Cre mice correlated 
with the delayed formation of fibrin at sites of vascular injury, 
suggesting that the pro-coagulant role of STIM1 and SOCE in 
platelets is critical for thrombus stability and growth. Thrombus 
instability observed in Stim1-/-, Orai1-/-, and Stim1f/f PF4-Cre 
mice, however, was not associated with a markedly increased 
bleeding risk as tested in a tail bleeding time assay. In summary, 
these studies suggest STIM1 and ORAI1 as novel targets for 
anti-platelet therapy.
STIM1- and ORAI1-independent Ca2+ entry in platelets 
STIM1 and ORAI1 are the major homologs expressed in plate-
lets, both at the RNA and protein level.97 However, platelets also 
express significant levels of STIM2, ORAI2, and ORAI3. So far, 
only mice lacking STIM2 were analyzed for platelet function. 
No defects in platelet activation in vitro and thrombus formation 
in vivo were observed in Stim2-/- mice.98 Studies in human plate-
lets also suggested a critical role of TRPC1 as a SOC channel in 
platelets. While it was initially assumed that TRPC1 is directly 
regulated by InsP
3
R-II,101 more recent studies suggested that 
TRPC1 channel activity is regulated by STIM1 and ORAI1.102 
Genetic deletion of TRPC1, however, did not affect platelet Ca2+ 
signaling and hemostasis in mice.103 Furthermore, Hassock and 
colleagues showed that TRPC1 expression in platelets is low and 
that it is predominantly found in internal membranes.104
While SOCE is the main mechanism of Ca2+ entry in plate-
lets, receptor-operated Ca2+ entry (ROCE) also contributes to 
this process. The ligand-gated cation channel P2X1 mediates 
fast Ca2+ entry induced by ATP. Ca2+ entry following selective 
activation of P2X1 is not sufficient to cause platelet aggregation. 
However, P2X1 contributes to collagen- and shear-induced plate-
let activation, and deficiency in this channel protects mice from 
experimental thrombosis.105,106 Studies in humans and mice iden-
tified TRPC6 as a diacylglycerol (DAG) activated ROC chan-
nel in platelets.104,107 Interestingly, genetic deletion of TRPC6 in 
mice had no effect on platelet function in vitro and in vivo, sug-
gesting that this ROC channel is dispensable for the hemostatic 
function of platelets at sites of vascular injury.
Lastly, the small-conductance Ca2+-activated nonselective 
























thapsigargin-induced SOCE and decreased SRC and AKT activ-
ity. Ablation of lipid raft formation in vivo by treatment of mice 
with methyl-β-cyclodextrin resulted in decreased tumor growth 
and prolonged survival in a B16 transfer model of melanoma.116 
A tumor growth-promoting role of SOCE was also shown in 
glioblastoma. Knockdown of ORAI1 or STIM1 reduced Ca2+ 
influx in C6 rat and U251 human glioblastoma cells, inhibited 
tumor cell proliferation and induced apoptosis.117 Interestingly, 
a genome-wide gene expression analysis in 20 patients with pri-
mary glioblastoma found increased expression of several genes 
including STIM2, but the functional consequences were not fur-
ther analyzed.118
Better documented is the role of STIM1 in cervical cancer. A 
study investigating 24 patients with cervical cancer found that 
the expression of STIM1 correlates with tumor size and clini-
cal outcome.40 71% of patients showed increased expression of 
STIM1 protein in primary cervical cancer tissue compared with 
that ORAI1 expression is regulated by androgens.115 Androgen 
deprivation of human LNCaP prostate cancer cells resulted in sig-
nificant reduction of ORAI1 protein levels and diminished SOC 
currents when compared with androgen-stimulated LNCaP cells. 
Moreover, knockdown of ORAI1 by siRNA decreased thapsi-
gargin-mediated SOCE and significantly lowered the susceptibil-
ity of LNCaP cells to a variety of apoptosis-inducing cytostatic 
drugs such as Cisplatin and Oxalaplatin.115
In contrast, several studies in a variety of cancer types find 
that SOCE – mediated by ORAI and STIM family proteins—
promotes tumor growth through a variety of mechanisms 
(Fig. 2). Fedida-Metula et al. showed that in murine B16-BL6 
melanoma cells, SOCE promotes cell proliferation by activat-
ing calmodulin and SRC kinase residing in lipid rafts.116 SRC 
kinase, in turn, inactivated the phosphatase PP2A, an important 
negative regulator of the growth promoting AKT/protein kinase 
B (PKB) signaling cascade. Knock down of STIM1 reduced 
Figure 2. The role of ORAI and STIM proteins in carcinogenesis. The second messenger Ca2+ plays an important role in regulating many signaling path-
ways related to cancer development and progression. SOCE in tumor  and endothelial cells results from the activation of cell surface receptors such as 
epidermal growth factor (EGF), vascular endothelial growth factor (VEGF) and secreted frizzled-related protein 2 (SFRP2). The subsequent activation of 
phospholipase C (PLC) leads to the production of InsP3 and release of Ca
2+ from ER Ca2+ stores via the opening of InsP3 receptor channels. The reduced 
Ca2+ concentration in the ER, or [Ca2+]ER, is sensed by stromal interaction molecule (STIM) 1, which binds to ORAI1, the pore-forming subunit of the Ca
2+ 
release-activated Ca2+ (CRAC) channel. Opening of CRAC channels results in Ca2+ influx and a sustained increase in intracellular Ca2+ levels, [Ca2+]i. Several 
cytoplasmic enzymes associated with cancer development and progression are regulated by Ca2+. ERK and AKT are phosphorylated in a Ca2+-dependent 
manner, whereas mRNA and protein levels of others molecules such as COX2 and cyclins are controlled by [Ca2+]i. SOCE has been linked to the regulation 
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discussed above, ORAI1 in this study was shown to mediate Ca2+ 
influx independent of Ca2+ store depletion and STIM1. Instead, 
the authors argue that ORAI1 is activated directly by binding 
of the secretory pathway calcium ATPase (SPCA2) to ORAI1 
as both proteins could be co-immunoprecipitated. Expression 
of SPCA2, known to regulate Ca2+ sequestration in the Golgi 
apparatus, was found to be higher in the MCF-7 adenocarcinoma 
cell line and primary breast tumor tissue compared with non-
malignant MCF-10A epithelial cells. Knockdown of SPCA2 in 
MCF-7 cells resulted in a small reduction of basal Ca2+ levels 
(without affecting SOCE) but significantly inhibited tumor cell 
proliferation in vitro and enhanced survival of mice injected with 
MCF7 breast cancer cells in a xenograft tumor model.123 The 
mechanisms by which SPCA2 regulates Ca2+ homeostasis and 
carcinogenesis remain to be elucidated.
SOCE controls migration and metastasis of cancer cells 
Besides its role in regulating tumor cell proliferation and 
apoptosis, STIM1 and ORAI1 have been found to affect the 
metastatis of cancer cells.41 Knockdown of STIM1 and ORAI1 
in human MDA-MB-231 breast cancer cells strongly decreased 
serum-induced cell migration in vitro despite only partial 
reduction in SOCE. In addition, ORAI1 or STIM1 knock-
down impaired the turnover of focal adhesion molecules such 
as vinculin and impaired generation of traction force in migrat-
ing MDA-MB-231 cells. In vivo, MDA-MB-231 cells depleted 
of ORAI1 or STIM1 and injected i.v. into SCID mice showed 
reduced numbers of lung metastases compared with untreated 
tumor cells. A similar reduction in metastatic lung foci was also 
observed when mice that had received MDA-MBA-231 cells by 
i.v. injection were treated with the non-selective SOCE inhibitor 
SKF 96365.41
Recent findings by Hu et al. suggest that STIM1 and ORAI1 
may also be involved in the epithelial-to-mesenchymal transition 
(EMT), which is a critical step in the tissue evasion and metastasis 
of tumor cells.124 The induction of EMT in human MCF-7 breast 
cancer cells by TGF-β1 was associated with downregulation of 
the transcription factor Oct4 and increased expression of STIM1 
and ORAI1 as well as augmented Ca2+ influx. Direct silencing 
of Oct4 resulted in ORAI1 and STIM1 upregulation, increased 
SOCE and enhanced migratory potential of MCF-7 cells in a 
transwell assay in vitro. Conversely, siRNA-mediated silencing of 
STIM1 expression in MCF-7 cells or inhibition of SOCE by the 
non-selective inhibitor 2-APB prevented EMT in breast cancer 
cells and reduced their migratory capacity.124 In addition to breast 
cancer cells, STIM1 may also regulate the metastatic potential of 
human cervical cancer cells. Of 24 patients with cervical cancer, 
those with pelvic lymph node metastasis had significantly higher 
levels of STIM1 expression in their primary tumors.40 Knock 
down of STIM1 in human SiHa cervical cancer cells decreased 
their ability to migrate in vitro by reducing the turnover and acti-
vation of focal adhesion proteins such as focal adhesion kinase 
(FAK).40
The Ca2+ dependent mechanisms that control tumor cell 
migration and metastasis are not yet fully understood. Expression 
of a constitutively active form of the Ca2+ dependent transcrip-
tion factor NFAT1 promoted the migration and invasion of 
adjacent non-cancerous tissue. The amount of STIM1 expression 
directly correlated with the size of the primary tumor and metas-
tasis; furthermore, the five year survival rate was significantly 
lower in patients with high levels of STIM1 expression. In vitro, 
stimulation of SiHa cervical cancer cells with epidermal growth 
factor (EGF) resulted in co-localization of STIM1 and ORAI1 
and the induction of Ca2+ oscillations. Knock-down of STIM1 
by siRNA not only abrogated Ca2+ influx in response to EGF but 
also inhibited the proliferation of SiHA cells. The latter was asso-
ciated with downregulation of the cell cycle promoter CDC25C 
and upregulation of the anti-proliferative protein p21.40 Ectopic 
overexpression of STIM1 in SiHA cells, by contrast, resulted in 
increased tumor growth in a xenograft model of cervical cancer 
in mice.40 A similar correlation between STIM1 expression and 
tumor growth was also shown in a cohort of 295 breast cancer 
patients.119 The survival of breast cancer patients with tumors 
expressing high STIM1 mRNA levels was significantly reduced 
compared with control groups. Together, these data indicate that 
STIM1 may play an important role in carcinogenesis.
In line with these findings, Faouzi et al. report a role of ORAI3 
in breast cancer. The expression of ORAI3 mRNA is increased 
in breast cancer tissue in the majority (76.9%) of patients from a 
small cohort of patients compared with healthy control tissue.120 
Knockdown of ORAI3 by siRNA in the human breast cancer 
cell lines MCF-7 and T47D reduced thapsigargin (TG)-induced 
SOCE, decreased cellular proliferation and promoted cell cycle 
arrest at the G1 stage. The latter was associated with upregula-
tion of p21 and downregulation of cyclin E, cyclin D, CDCK2 
and CDCK4. Reduced ORAI3 expression resulted in increased 
apoptosis of MCF-7 cancer cells but not non-malignant control 
MCF-10a epithelial cells.120 A similar increase in ORAI3 expres-
sion in breast cancer cell lines was noted by Motiani et al., espe-
cially those expressing estrogen receptors (ER+).121 SOCE in ER+ 
breast cancer cells was found to be mediated by ORAI3 (and 
STIM1), whereas ER- breast cancer cells or normal epithelial 
cells depended on ORAI1 (and STIM1) for SOCE. Expression of 
ORAI3, but not that of ORAI1, appears to be directly regulated 
by ER, as knockdown of ERα resulted in a selective decrease in 
ORAI3 levels and SOCE, whereas treatment of ER+ MCF7 breast 
cancer cells with 17β-estradiol enhanced ORAI3 expression and 
SOCE. Interfering with ORAI3 expression in MCF7 cells inhib-
ited their anchorage-independent growth in soft agar assays and 
tumor cell invasion in matrigel assays in vitro.122 Importantly, the 
growth of breast tumors in vivo was significantly reduced when 
ORAI3 expression in MCF7 cells was knocked down by shRNA 
before transfer to recipient SCID mice, suggesting that ORAI3 
controls SOCE in ERα+ breast cancer cells and their growth in 
vivo.122 It is noteworthy, however, that a similar predominance 
of ORAI3 channels in ER+ MCF7 or ER- MDA-MB-231 breast 
cancer cell lines was not observed in another study, in which 
ORAI1 knock-down impaired SOCE and cancer cell growth.119 
Nevertheless, the data discussed above suggest an intriguing con-
nection between ORAI3 and cancer development and provide a 
first insight into the endogenous role of ORAI3 channels.
A potentially important role for ORAI1 in breast cancer patho-

























The emerging role of SOCE mediated by ORAI and STIM 
proteins in a variety of disease processes has important clinical 
implications as it suggests that CRAC channel inhibition can 
potentially be used for the treatment of, for instance, autoim-
mune diseases and inflammation, thrombosis or cancer progres-
sion and metastasis. Inhibition of SOCE by genetic deletion of 
Stim1 protected mice from T-cell mediated CNS inflammation 
in an animal model of multiple sclerosis (MS) and intestinal 
inflammation in a model of Crohn’s disease.29,31,33 This protec-
tion was due to impaired function of Th1 and Th17 cells, which 
produce proinflammatory cytokines such as IFN-γ and IL-17A. 
It is noteworthy that STIM2-deficient mice were partially resis-
tant to EAE consistent with their partial defect in SOCE and 
cytokine production in T cells.29 These findings suggest that pro-
inflammatory Th1 and Th17 cells require strong and sustained 
SOCE to induce cytokine expression and to mediate autoim-
mune inflammation. By contrast, the function of other immune 
cells such a Foxp3+ Treg cells and CD8+ cytotoxic T cells (CTL) 
is less dependent on CRAC channels as only complete deletion 
of SOCE in STIM1,2-deficient mice impaired their function32 
(SF, CW, unpublished observation), thereby potentially provid-
ing a large therapeutic window for CRAC channel inhibition in 
inflammatory diseases.
In platelets, SOCE depends predominantly on STIM1 and 
ORAI1. Studies in mice lacking functional STIM1 or ORAI1 
demonstrated that inhibition of SOCE could be an effec-
tive strategy to prevent thrombosis without increasing the risk 
of bleeding. Such novel therapies, however, would have to be 
targeted specifically toward platelets in order to avoid adverse 
effects on the various other cells that depend on SOCE. Such 
specificity toward platelets could be achieved by (a) targeted 
delivery of the drug to circulating platelets, or (b) the identifica-
tion of compounds that predominantly affect the function of 
STIM1 or ORAI1 in platelets. The latter will depend on a better 
understanding of the fine-tuning of SOCE in platelets and other 
cells, i.e., the identification of posttranslational modifications in 
STIM1 and ORAI1 that are unique to platelets. Another line 
of research will have to investigate why SOCE is critical for the 
pro-coagulant rather than the pro-adhesive response of plate-
lets, even though Ca2+ signaling via CalDAG-GEFI is a central 
event in the inside-out activation of the major platelet adhesion 
receptor, integrin αIIbβ3. Our studies so far suggest that Ca2+ 
released from intracellular stores in response to stimulation by 
well-known platelet agonists is the main trigger of CalDAG-
GEFI-dependent platelet activation. It will be interesting to see if 
there are pathophysiological situations where SOCE rather than 
store release controls platelet adhesion. Lastly, we need a better 
understanding of the molecular mechanisms linking SOCE to 
platelet pro-coagulant responses. Calcium is known to regulate 
proteins like calpain and Ca2+-sensitive scramblase, which are 
critical for surface expression of PS and the binding of soluble 
clotting factors. Calcium overload also leads to the disruption 
of mitochondrial integrity and the formation of the mitochon-
drial transition pore, another requirement for the conversion 
breast cancer cells in vitro.125 NFAT regulates the expression 
of genes that play important roles in EMT including autotaxin 
and cyclooxygenase 2 (COX2). Both are secreted enzymes that 
mediate the production of lysophosphatidic acid (LPA) and 
prostaglandin E2 (PGE2), respectively. LPA and PGE2 bind to 
receptors on breast epithelial or other cells and promote their 
migration and tissue invasion.126 siRNA mediated knockdown 
of COX2 in highly metastatic breast cancer cells, for instance, 
reduced transmigration of tumor cells across an artifical blood 
brain barrier in vitro and decreased brain metastasis in mice in 
vivo.127 Huang et al. recently showed that histamine stimulation 
evokes SOCE in human lung cancer cells and results in COX2 
expression, indicating a potential link between COX2 and Ca2+ 
influx. Following the depletion of ORAI1 by siRNA or inhibi-
tion of SOCE by 2-APB, COX2 expression and NF-kB activa-
tion were inhibited.128 Furthermore, deletion of the distal part of 
the COX2 promoter containing two NF-kB binding sites abol-
ished COX2 expression suggesting that histamine/Ca2+ depen-
dent COX2 expression is mediated by NF-kB. It is likely that 
other Ca2+ regulated factors besides NFAT and NF-kB regulate 
EMT and metastasis as well.
SOCE in neovascularization of tumors 
Chen et al. observed that SOCE is important for the formation 
of blood vessels inside tumors by controlling the secretion of vas-
cular endothelial growth factor (VEGF) by cervical cancer cells.40 
Knockdown of STIM1 in human cervical cancer cells resulted in 
diminished secretion of VEGF. In vivo, cervical tumors in SCID 
mice injected with SiHA tumor cells showed decreased neovascu-
larization after i.v. injection with the non-selective SOCE inhibi-
tors 2-APB and SKF 96365.40 Interestingly, not only did SOCE 
control VEGF secretion by tumor cells, but VEGF itself is known 
to increase [Ca2+]
i
 after binding to its receptor VEGFR through 
activation of PLCγ and induction of SOCE in human endothelial 
cells. Silencing of STIM1 or ORAI1 by siRNA reduced VEGF-
mediated Ca2+ influx in human HUVEC cells and impaired their 
proliferation.129 Consistent with these findings, Dragoni et al. 
observed that stimulation of human endothelial progenitor cells 
(EPC) with VEGF induced Ca2+ oscillations. Treatment of cells 
with the CRAC channel inhibitor BTP-2 reduced Ca2+ oscilla-
tions, cell proliferation and tubologenesis in vitro.130 The Ca2+ 
dependent mechanisms controlling neovascularization in tumors 
have not been studied directly, but are likely to involve Ca2+ 
dependent transcription factors such as NFAT.126,131 NFAT was 
shown to regulate expression of molecules essential for endothe-
lial cell migration, tube formation and angiogenesis such as tissue 
factor (TF)132,133 and cyclooxygenase (COX) 2.127,134,135 Increased 
expression of inhibitors of the calcineurin-NFAT pathway such 
as the calcineurin suppressor DSCR1 results in decreased tumor 
angiogenesis and tumor growth due to attenuated NFAT acti-
vation.136 In addition, shRNA-mediated knock down of NFAT4 
(NFATc3) in 2H11 endothelial cells prevented endothelial 
tube formation in vitro in response to the pro-angiogenic fac-
tor secreted frizzled-related protein 2 (SFRP2).137 Treatment of 
MMTV-neu transgenic mice, a rodent breast cancer model, with 
the NFAT inhibitor tacrolimus significantly decreased the den-
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may be offset by the concommittant suppression of antitumor 
immunity by cytotoxic CD8+ T cells and natural killer (NK) 
cells that require SOCE for their function.51,139 Calcineurin 
inhibitors (cyclosporin, tacrolimus) have been considered as 
potential cancer therapeutics because they inhibit NFAT acti-
vation, which regulates expression of tumor promoting factors 
such as COX2, autotaxin and VEGFR.126 Nevertheless, long-
term immunosuppressive treatment with cyclosporine acceler-
ates the development of skin cancers and lymphoproliferative 
disorders in human patients.140 This may be due to effects of 
calcineurin inhibition on antitumor immunity or cancer cell 
intrinsic effects as cyclosporine was shown to increase the 
motility and invasive growth of adenocarcinoma cells.141 For the 
reasons discussed above, additional studies are required to bet-
ter understand the role of SOCE and ORAI/STIM proteins in 
carcinogenesis.
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of platelets to a pro-coagulant state.138 The contribution of 
STIM1 and ORAI1 to these processes, however, is not fully 
understood.
Recent evidence suggests that the expression of STIM and 
ORAI proteins is dysregulated in several types of human cancer 
and that SOCE may be a critical regulator of carcinogenesis. 
For instance, SOCE is involved in controlling proliferation and 
apoptosis of cancer cells, tumor neovascularization and expres-
sion of enzymes such as COX2 and autotaxin – thereby regulat-
ing the migration and tissue invasion of tumor cells. While the 
majority of studies suggest that SOCE is pro-oncogenic, it is too 
early for a conclusive interpretation of how SOCE affects car-
cinogenesis. To date, most experiments investigating the role of 
SOCE in cancer have been performed in cell lines; future stud-
ies will have to analyze how ORAI and STIM affect carcino-
genesis in vivo. Initial in vivo studies demonstrated that SOCE 
controls the growth and metastasis of breast and cervical can-
cer; whether this is a general feature of carcinogenesis or specific 
to these tumors remains to be investigated. Furthermore, the 
molecular mechanisms by which SOCE regulates tumor growth 
and metastasis are still poorly understood. The multiple roles for 
SOCE in carcinogenesis and metastasis make CRAC channels 
an attractive drug target for tumor therapy. It is important to 
keep in mind, however, that STIM1 was initially found to be a 
tumor suppressor in rhabdomyosarcoma and prostate cancer cell 
lines. In addition, the positive effects of CRAC channel inhibi-
tion on the growth or invasive behavior of certain tumors types 
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